Real‐world study of the concomitant use of biphasic insulin aspart 30/70 with GLP‐1 receptor agonist versus first‐generation basal insulin with GLP‐1 receptor agonist in type 2 diabetes
Authors' conclusion
Combining BIAsp 30 + GLP-1RA provides glycaemic control with no significant difference to that of propensity score-matched people receiving basal insulin+GLP-1RA, with no increase in hypoglycaemia risk or weight gain.
Study context
- Population
- People with T2D, Clinical Practice Research Datalink Aurum database, England, 2006–2021eligible identified
- Participants
- 4,770 people
- Exposure
- BIAsp 30 + GLP-1 RA vs basal insulin + GLP-1 RA
- BIAsp 30 + GLP-1RAn = 1,511
- Outcome
- HbA1c reduction
- Follow-up
- 6 months
Methodological detailspropensity score matching
- Propensity score matching
Main finding
As reported in the abstract
| Group | Value | Mmol/mol |
|---|---|---|
| BIAsp 30 + GLP-1RA | −1.07 (95% CI −1.16–-0.98) %-points | −11.7 (95% CI: −12.7; −10.7) |
| basal+GLP-1RA | −0.97 (95% CI −1.07–-0.88) %-points | −10.6 (95% CI: −11.7; −9.6) |
Value
BIAsp 30 + GLP-1RA−1.07 (95% CI −1.16–-0.98) %-points
basal+GLP-1RA−0.97 (95% CI −1.07–-0.88) %-points
Mmol/mol
BIAsp 30 + GLP-1RA−11.7 (95% CI: −12.7; −10.7)
basal+GLP-1RA−10.6 (95% CI: −11.7; −9.6)
- BIAsp 30 + GLP-1RA vs basal+GLP-1RA: P = 0.15 — no significant difference
Observational data: associations, not effects.
Further findings
kg/m²
| Outcome | BIAsp 30 + GLP-1RA | basal+GLP-1RA | P value |
|---|---|---|---|
| BMI change · 6 months | −0.35 (95% CI −0.52–-0.18) | −0.72 (95% CI −0.90–-0.54) | P = 0.003 |
- Body mass index (BMI) change — BMI influenced by initiation sequence of GLP-1 RA relative to insulin
- p < 0.0001
Safety
- Hypoglycaemia rates were low and not significantly different between cohorts
Original publication
Real‐world study of the concomitant use of biphasic insulin aspart 30/70 with GLP‐1 receptor agonist versus first‐generation basal insulin with GLP‐1 receptor agonist in type 2 diabetes. Diabet Med. Published 13 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →